Steminent Biotherapeutics Inc. (TPEX:7729)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
82.70
+4.40 (5.62%)
Apr 28, 2026, 2:00 PM CST
258.79%
Market Cap 5.51B
Revenue (ttm) n/a
Net Income (ttm) -174.04M
Shares Out 66.63M
EPS (ttm) -2.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 523,267
Average Volume 398,343
Open 78.90
Previous Close 78.30
Day's Range 75.10 - 83.10
52-Week Range 19.55 - 95.60
Beta 0.70
RSI 53.49
Earnings Date Apr 29, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7729
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.